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Abstract
Background: Inhibition of vascular smooth muscle cell (vSMC) proliferation by oral anti-hyperglycemic agents may have
a role to play in the amelioration of vascular disease in diabetes. Thiazolidinediones (TZDs) inhibit vSMC proliferation
but it has been reported that they anomalously stimulate [3H]-thymidine incorporation. We investigated three TZDs,
two biguanides and two sulfonylureas for their ability of inhibit vSMC proliferation. People with diabetes obviously have
fluctuating blood glucose levels thus we determined the effect of media glucose concentration on the inhibitory activity
of TZDs in a vSMC preparation that grew considerably more rapidly under high glucose conditions. We further explored
the mechanisms by which TZDs increase [3H]-thymidine incorporation.
Methods: VSMC proliferation was investigated by [3H]-thymidine incorporation into DNA and cell counting. Activation
and inhibition of thymidine kinase utilized short term [3H]-thymidine uptake. Cell cycle events were analyzed by FACS.
Results: VSMC cells grown for 3 days in DMEM with 5% fetal calf serum under low (5 mM glucose) and high (25 mM
glucose) increased in number by 2.5 and 4.7 fold, respectively. Rosiglitazone and pioglitazone showed modest but
statistically significantly greater inhibitory activity under high versus low glucose conditions (P < 0.05 and P < 0.001,
respectively). We confirmed an earlier report that troglitazone (at low concentrations) causes enhanced incorporation
of [3H]-thymidine into DNA but did not increase cell numbers. Troglitazone inhibited serum mediated thymidine kinase
induction in a concentration dependent manner. FACS analysis showed that troglitazone and rosiglitazone but not
pioglitazone placed a slightly higher percentage of cells in the S phase of a growing culture. Of the biguanides, metformin
had no effect on proliferation assessed as [3H]-thymidine incorporation or cell numbers whereas phenformin was
inhibitory in both assays albeit at high concentrations. The sulfonylureas chlorpropamide and gliclazide had no inhibitory
effect on vSMC proliferation assessed by either [3H]-thymidine incorporation or cell numbers.
Conclusion: TZDs but not sulfonylureas nor biguanides (except phenformin at high concentrations) show favorable
vascular actions assessed as inhibition of vSMC proliferation. The activity of rosiglitazone and pioglitazone is enhanced
under high glucose conditions. These data provide further in vitro evidence for the potential efficacy of TZDs in preventing
multiple cardiovascular diseases. However, the plethora of potentially beneficial actions of TZDs in cell and animal
models have not been reflected in the results of major clinical trials and a greater understanding of these complex drugs
is required to delineate their ultimate clinical utility in preventing macrovascular disease in diabetes.
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Background
The role of vascular smooth muscle cell (vSMC) prolifera-
tion in vascular disease, particularly atherosclerosis, is
controversial and unresolved [1]. However, emerging
information is identifying the situations such as post-
angioplasty restenosis in people with diabetes in which
hyperproliferation is clearly critical in determining the
clinical outcome [2]. Although coronary artery by-pass
grafting (CABG) was initially the preferred intervention
over angioplasty in people with diabetes and coronary
artery disease [3] the introduction of coronary artery
stents and drug coated stents and possibly supplemented
with systemic therapy has raised the possibility that this
less invasive treatment may be suitable for this population
[4,5]. Although factors such as proteoglycan mediated
lipid deposition [6,7] and inflammation [8,9] are clearly
important in the process of atherosclerosis and restenosis,
in the setting of diabetes vSMC proliferation is clearly crit-
ical and thus a target for therapy [2]. As people with dia-
betes clearly have ongoing hyperglycemia after a clinical
intervention for coronary artery disease (CAD), the role of
the anti-hyperglycemic therapy in providing a comple-
mentary action to prevent vSMC cell proliferation is of
potential therapeutic interest [10]. It is further possible
that an oral anti-proliferative agent may also be useful as
adjunct therapy following vascular intervention even in
the absence of diabetes [11].
We have made a direct comparison of the inhibitory activ-
ity of the three major classes of oral anti-hyperglycemic
agents thiazolidinediones (TZDs) also known as glita-
zones, biguanides and sulphonylureas towards vSMC pro-
liferation. Further, we used multiple assays to evaluate the
mechanism of inhibition and addressed the clinically rel-
evant question of the effect of glucose concentration on
the inhibitory activity of the TZDs.
The data shows that only TZDs show appreciable inhibi-
tory activity towards vSMC proliferation amongst cur-
rently used oral anti-hyperglycemic agents. Furthermore,
under high glucose conditions in which vSMC prolifera-
tion is markedly enhanced, the inhibitory potency of the
clinical TZDs, rosiglitazone and pioglitazone, is increased
not diminished. We also reveal an action of TZDs to stim-
ulate [3H]-thymidine incorporation secondary to stimula-
tion of uptake suggesting that other assays of proliferation
are more suitable for studies with this class of drug.
Methods
Materials
Phenformin, metformin, chlorpropamide, dimethylsul-
foxide (DMSO), platelet-derived growth factor (PDGF),
Whatman 3 MM chromatography paper and DEAE-
Sephacel were obtained from Sigma Aldrich (St Louis,
MO). Gliclazide was provided by Institute de Recherches
Internationale Servier (France). Troglitazone (Rezulin,
Parke-Davis/Warner Lambert), rosiglitazone (Avandia,
GlaxoSmithKline) and pioglitazone (Actos, Takeda) were
provided as gifts by Parke Davis Pharmaceutical Research
(Ann Arbor, MI), GlaxoSmithKline (Boronia, Australia)
and Eli Lilly (West Ryde, Australia), respectively. Foetal
bovine serum (FBS) was obtained from CSL (Parkville,
Australia). [3H]-Thymidine and cetylpyridinium chloride
(CPC) were from ICN Biomedicals Inc. (Irvine, CA). Scin-
tillation fluid Instagel was from Packard (Groningen, The
Netherlands).
Cell culture preparations
Human vSMCs were isolated using the explant technique
from discarded segments of the saphenous veins and
internal mammary arteries from a variety of patient
donors undergoing surgery at the Alfred Hospital (Mel-
bourne, Australia), the acquisition of which was approved
by the Alfred Hospital Ethics committee. Cells from both
sources were used for these experiments and in accord
with our recent data [12] there were no systematic differ-
ences in the results obtained with cells from either vascu-
lar origin.
Analysis of mitogenic response by 3H-thymidine 
incorporation
Cells were seeded at 4.5 × 104 cells per well in a 24 well
plate in DMEM containing 5 mM glucose with 10% FBS
for 24 h. Cells were serum deprived for 48 h followed by
treatment with control media (0.1% DMSO) or treatment
media containing the anti-hyperglycaemic agents in the
presence of PDGF (50 ng/ml) and incubated overnight at
37°C in 5% CO2. Cells were labelled with [3H]-thymidine
(1 μCi/ml) or 3 h and assessed for [3H] incorporation into
newly synthesized DNA as previously described [13].
Analysis of cell proliferation by assessment of cell number
Human vSMCs in the log growth phase were treated with
anti-hyperglycaemic agents (10–300 μM) in the presence
of 5% serum for 72 h and assessed for cell number as pre-
viously described [12].
Assessment of thymidine kinase induction by acute [3H]-
thymidine uptake
Acute [3H]-thymidine uptake was assessed as previously
described [14]. Briefly, vSMCs were grown to confluency
in 24 well plates and serum deprived for 24 h in DMEM
(5 mM glucose) and 0.1% FCS. Growth factors and drugs
as indicated were added for 18 h. The cells were washed
once with DMEM (5 mM glucose) prior to an equilibrat-
ing 30 min incubation in DMEM (5 mM glucose). [3H]-
Thymidine (1 μCi/ml) was added and uptake proceeded
for 4 mins at 37°C. At the end of the incubation period,
the cells were immediately placed on ice and rapidly
washed with ice cold PBS. The radioactivity was releasedCardiovascular Diabetology 2007, 6:33 http://www.cardiab.com/content/6/1/33
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into solution by 1 M NaOH. The amount of [3H]-thymi-
dine was quantitated by liquid scintillation counting.
Cell cycle analysis by Fluorescence Activated Cell Sorting 
(FACS)
Cells were seeded at 2.5 × 105 cells per 90 mm plate in
duplicate in DMEM containing 5 mM glucose with 10%
FBS for 24 h. Cells were serum deprived for 48 h followed
by treatment with control media (0.1% DMSO) or treat-
ment media containing the anti-hyperglycaemic agents in
the presence of PDGF (50 ng/ml) in the presence of 5%
serum and incubated for 72 h at 37°C in 5% CO2. For
analysis of S phase entry and cells were labelled with 10
μM 5-bromo-2'-deoxyuridine (BrdU, Sigma, St. Louis,
MO) for 4 hr at 37°C in the culture medium. BrdU incor-
poration was detected using FITC-conjugated anti-BrdU
(Becton Dickinson) and DNA was stained with propid-
ium iodide (5 μg/ml) 30 min at room temperature in the
dark. Flow cytometry and cell cycle analysis was carried
out with a FACS Calibur (Becton Dickinson) with 488 nm
excitation.
Statistical analyses
Data are presented as mean ± standard error of the mean
(SEM) from 2–5 experiments as indicated in each individ-
ual figure. Data were statistically analysed using a Stu-
dent's t test or 1-way ANOVA.
Results
Inhibition of vSMC proliferation by TZDs – dependence of 
the inhibitory activity of TZDs on the culture media 
glucose concentration
People with diabetes have blood glucose concentrations
that may range at times from 2 to 30 mM and thus the
effect of glucose concentration on the actions of anti-
hyperglycaemic agents is clinically relevant. We identified
a human vSMC preparation that showed enhanced prolif-
eration in response to high glucose media. Under "low"
glucose conditions which actually equate to normoglyc-
emia (i.e. DMEM with 5 mM glucose) and in the presence
of 5 per cent FBS, cell numbers over 3 days increased from
36,800 ± 3,800 to 91,900 ± 8500 cells/well (mean ± sem,
n = 5 experiments in triplicate). Under high glucose con-
ditions (DMEM containing 25 mM glucose) and in the
presence of 5 per cent FBS, vSMC numbers increased from
54,400 ± 5500 to 250,500 ± 28,000 cells/well (mean ±
sem, n = 5 experiments in triplicate). We used this cell
model to assess the inhibitory activity of the two clinical
TZDs, rosiglitazone and pioglitazone. Rosiglitazone was
evaluated at 3–100 μM and pioglitazone 0.3–30 μM not-
ing that pioglitazone precipitates in the culture media at
concentration above 30 μM. The inhibitory effects of ros-
iglitazone in low and high glucose media were normal-
ised to the control which was set as 100% (Fig. 1A and 1B,
respectively). The data is presented as a dose response
curve with statistical comparison of the curves (Fig. 1C).
The data shows that the inhibitory effect of rosiglitazone
is enhanced (P < 0.05) under high glucose condition (Fig.
1C). Similar data for the effect of pioglitazone is shown in
(Figs 1D, E and 1F). Pioglitazone showed a greater inhib-
itory potency (P < 0.001) in high compared to low glucose
DMEM.
Evaluation of the effect of TZDs as assessed by [3H]-
thymidine incorporation
Multiple assays have been used to evaluate the inhibitory
effects of TZDs on vSMC proliferation. Takeda et al. [15]
have reported that TZDs cause a marked but anomalous
increase in [3H]-thymidine incorporation in vSMCs and it
was further suggested that this is associated with a hyper-
proliferative response [15]. We investigated the effects of
troglitazone, the TZD used by those authors, on the [3H]-
thymidine incorporation by human vSMCs. Troglitazone
had a bi-phasic effect on [3H]-thymidine incorporation
into DNA with stimulation at low concentrations and
inhibition at higher concentrations (Fig. 2). We investi-
gated the mechanism of this increase in [3H]-thymidine
incorporation which is at variance with the inhibition
observed when inhibition of proliferation is assessed by
cell counting as we previously described [12].
Activation of [3H]-thymidine incorporation into DNA of
proliferating cells arises from growth factor mediated acti-
vation of thymidine kinase activity and enhanced [3H]-
thymidine uptake into the salvage pathway of thymidylate
synthesis which provides adequate precursors for DNA
synthesis in vSMC [14]. We hypothesized that troglita-
zone may have a growth factor like effect (gene induction)
on thymidine kinase leading to enhanced uptake and con-
sequently increased incorporation of [3H]-thymidine into
DNA. Thymidine kinase activity can be assessed as the
uptake by the cell of [3H]-thymidine over a period of sev-
eral minutes [14]. We treated vSMCs with low (0.3 μM)
and high (10 μM) concentrations of troglitazone which
stimulate and inhibit, respectively, [3H]-thymidine incor-
poration into DNA precipitable material (Fig. 2). We
undertook the acute (3 min) uptake experiment concom-
itant with an examination of the effect of troglitazone on
incorporation of [3H]-thymidine into DNA in a parallel
experiment as described above. Troglitazone caused con-
centration dependent inhibition of the acute uptake of
[3H]-thymidine (Fig. 3A) with no evidence of stimulation.
The parallel experiment for assessing [3H]-thymidine
incorporation into DNA produced the expected result of
enhanced [3H]-thymidine incorporation at low concen-
tration of troglitazone (0 – 3 μM) and inhibition of incor-
poration at high troglitazone concentrations (10 nM)
(Fig. 3B).Cardiovascular Diabetology 2007, 6:33 http://www.cardiab.com/content/6/1/33
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Effect of media glucose concentration on the inhibitory activity of TZDs Figure 1
Effect of media glucose concentration on the inhibitory activity of TZDs. Panels A and B show the effect of rosiglita-
zone under low (5 mM) glucose (A) and high glucose (25 mM) and the data shown as a dose response curve (C). Data for 
pioglitazone is shown in panels D, E and F. Data represent the mean ± SEM from 3 experiments in triplicate *P < 0.05, ***P < 
0.001
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Troglitazone treatment of vSMC increases [3H]-thymidine
incorporation into newly synthesized DNA which implies
that more cells are in the S phase of the cell cycle. We used
FACS to investigate the effects of the three TZDs on cell
cycle progression in vSMCs. The treatment of vSMCs with
troglitazone and rosiglitazone resulted in a small increase
in cells in the S phase (Fig. 4). In contrast, treatment of
cells with pioglitazone reduced the proportion of cells in
the S phase of the cell cycle (Fig. 4). The data indicates that
the [3H]-thymidine incorporation truly reflects an
increased number of cells in the S phase in the presence of
rosiglitazone and troglitazone however this does not
result in cell cycle progression as no increase in cell num-
bers is observed [12].
Effect of biguanides on vSMC proliferation
The effects of metformin and phenformin were assessed as
described above. Although phenformin has been with-
drawn from clinical use, its use also allowed us to assess
two compounds in the biguanide class. Metformin had no
inhibitory effect on [3H]-thymidine incorporation stimu-
lated by PDGF and indeed a small anomalous stimulatory
effect at 30 μM that attained statistical significance (Fig.
5A). Phenformin (10, 30, 100 μM) caused a partially con-
centration dependent inhibitory response with a half
maximal inhibitory concentration of approximately 30
μM (Fig. 5A). In terms of vascular pathology the response
of most interest is that of changes in cell number. Thus we
examined the effect of metformin and phenformin on
serum-stimulated increases in cell number. Metformin
had no effect on cell numbers but phenformin caused a
concentration dependent reduction in cell proliferation
with a half maximally inhibitory concentration between
30 and 100 μM (Fig. 5B). There were no apparent toxic
effects of phenformin on the cells as assessed by lactate
Effect of TZDs on the induction of thymidine kinase assessed  by acute [3H]-thymidine uptake and parallel estimation of  [3H]-thymidine incorporation into DNA Figure 3
Effect of TZDs on the induction of thymidine kinase 
assessed by acute [3H]-thymidine uptake and parallel 
estimation of [3H]-thymidine incorporation into 
DNA. A. Confluent serum deprived vSMCs were treated 
with PDGF with and without troglitazone for 20 h then cells 
were washed free and growth factor and drugs and the acute 
uptake of [3H]-thymidine over 4 min was assessed. The 
results show the effects of two identical experiments in 
duplicate. B. Shows concomitant data for routine assay of 
[3H]-thymidine into DNA (see methods for details).
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Effect of troglitazone on PDGF stimulated [3H]-thymidine  incorporation into DNA Figure 2
Effect of troglitazone on PDGF stimulated [3H]-thy-
midine incorporation into DNA. The experiment was 
conducted exactly as described in the methods utilising trogl-
itazone (0.1 – 10 μM). The experiment shown is representa-
tive of two further experiments in duplicate.
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dehydrogenase release and phase contrast microscopy
(data not shown).
Effect of sulphonylureas on vSMC proliferation
We examined the effect of two representative sulfonylu-
reas on the inhibition of cell cycle S-phase [3H]-thymidine
incorporation into human vSMCs stimulated by PDGF
[16]. Neither chlorpropamide (10, 30, 100 μM) nor gli-
clazide (10, 30, 100 μM) inhibited the ability of PDGF to
stimulate [3H]-thymidine incorporation even at high con-
centrations (data not shown). We also assessed the effect
of chlorpropamide (3–100 μM) and gliclazide (3–100
μM) to inhibit proliferation assessed by cell counting.
Chlorpropamide and gliclazide had no effect on cell pro-
liferation stimulated by 5 per cent fetal bovine serum
(FBS) assessed after 3 days proliferation (data not shown).
Discussion
We have systematically evaluated the effect of the three
major classes of oral anti-hyperglycaemic agents for their
ability to inhibit vSMC proliferation using the techniques
of [3H]-thymidine incorporation into DNA and cell
counting plus supporting mechanistic studies. We con-
firmed our earlier report that all three clinically used TZDs
cause concentration dependent inhibition of vSMC prolif-
eration assessed by cell counting [12]. Utilizing human
vSMCs that showed glucose dependent cell proliferation
(accelerated growth under high glucose conditions) we
demonstrated that the inhibitory potency of rosiglitazone
and pioglitazone was slightly but statistically significantly
greater under high glucose conditions. A representative
TZD, troglitazone showed an unexpected but previously
observed effect to stimulate [3H]-thymidine incorporation
into DNA at low concentrations with clear and marked
inhibition at high concentrations. We investigated the
possibility that the stimulation was secondary to induc-
tion of thymidine kinase activity and thus acute stimula-
tion of [3H]-thymidine uptake but this was not the
mechanism. However, cell cycle analysis by FACS con-
firmed that the increase in [3H]-thymidine incorporation
correlated with the increase in cells in the S phase of the
Effect of metformin and phenformin on vascular smooth  muscle cell proliferation assessed by thymidine incorporation  and cell counting Figure 5
Effect of metformin and phenformin on vascular 
smooth muscle cell proliferation assessed by thymi-
dine incorporation and cell counting. A. Human vSMCs 
were treated with metformin (10–100 μM) and phenformin 
(10–100 μM) in the presence of PDGF (50 ng/ml) and 
assessed for [3H]-thymidine incorporation. Data represent 
the mean ± SEM, *P < 0.05 vs PDGF. B. Human vSMCs were 
treated with metformin (10–300 μM) and phenformin 
(10–300 μM) in the presence of 5% serum for 3 days and 
then counted on a Coulter counter. Data represent the 
mean ± SEM from 2 experiments in triplicate **P < 0.01, ***P 
< 0.001 vs the 5% FBS.
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Assessment of the cell cycle state of human vSMCs following  treatment with clinical TZDs Figure 4
Assessment of the cell cycle state of human vSMCs 
following treatment with clinical TZDs. S phase frac-
tion in cultures treated with TZDs either Troglitazone, Ros-
iglitazone or Pioglitazone (1 μM each) in the presence of 
PDGF (50 ng/mL) for 24 h as compared with untreated con-
trols. S phase fraction was analysed by flow cytometry using 
DNA staining with propidium iodide.
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cell cycle. Two sulfonylureas showed no inhibitory activ-
ity in the former assay and were not further investigated.
Of the two biguanides only phenformin, which is not
now clinically used, showed inhibitory activity and this
was expressed in both the assay of [3H]-thymidine incor-
poration into DNA and cell counting. Thus of the clini-
cally relevant oral hypoglycemic agents only the TZDs
showed inhibition of vSMC proliferation.
The major clinical implication of these studies relates to
the role of vSMC proliferation in cardiovascular disease.
The most prominent finding is that the diabetic milieu
leads to hyper proliferation of vSMCs such that in people
with diabetes proliferation limits the efficacy of vascular
interventions due to hyperplasia of vSMCs [2]. Such pro-
liferation also occurs in animal models such as the strep-
tozotocin treated mini pigs in which a clear development
of vascular hyperplasia occurs in association with
increased expression of inflammatory markers [17]. Thus,
there may be a role for choosing an oral hypoglycemic
agent with anti-proliferative actions to provide additional
potential benefit for people with diabetes. Indeed rosigli-
tazone has been shown to limit the increase in intimal
medial thickening and restenosis in people with diabetes
[4,11]. Our demonstration that the anti-proliferative
action of TZDs is maintained even enhanced in a high glu-
cose environment favors the use of these agents for glu-
cose lowering in people with diabetes although the
overall impact of these agents on cardiovascular disease is
the subject of considerable controversy as addressed later
[18,19].
The impact of hyperglycemia on the actions of TZDs on
cardiovascular cells is an important aspect of the action of
anti-hyperglycemic agents, particularly for TZDs which
are being considered for wider use in the cardiovascular
setting. We are unaware of any reports of the effect of glu-
cose concentration on the cellular action of clinical TZDs
in any in vitro setting. There are many examples where
high glucose stimulates responses relevant to diabetes
[20,21] and it is possible that such stimulation may
oppose or sensitize to the actions of TZDs. In our experi-
ments we observed that the activity of pioglitazone and
rosiglitazone to inhibit human vSMC proliferation was
enhanced under high glucose conditions. It is obviously
desirable that the proposed beneficial actions of TZDs not
be lost under the hyperglycemia of diabetes.
The unexpected stimulatory effect of troglitazone on [3H]-
thymidine incorporation [15] does not represent
increased cell growth since clearly the cell numbers arising
in the presence of the TZD are reduced [12]. The cell cycle
has two transition points known as point A in the G1
phase and point Q in the G2 phase; these are points of hes-
itation that add a stochastic element to the cell cycle [22].
The data suggest that TZDs, or at least troglitazone, per se,
can progress vSMC through point A of the cell cycle which
leads to S phase DNA synthesis and thus [3H]-thymidine
incorporation however progression through point Q does
not appear to be driven by these agents [22]. We showed
that the increase in [3H]-thymidine incorporation does
not arise from activation of thymidine kinase and thus the
mechanism remains unresolved. We have observed in
other experiments that TZDs alter glucose metabolism in
a manner that perturbs radiolabel incorporation into
vSMC proteoglycans (Nigro and Little, unpublished
observations) so it is possible that these agents also per-
turb intracellular nucleotide metabolism in a manner that
alters the specific activity of thymidine precursor pools
utilized for DNA synthesis. The data indicates that for this
drug class, assessment of [3H]-thymidine incorporation is
not a suitable assay. We have previously demonstrated
that the assay of [3H]-thymidine incorporation into DNA
greatly over estimates the inhibitory effect of the calcium
antagonist class of anti-hypertensive drugs [14]. Calcium
antagonists acutely block the uptake of [3H]-thymidine
but because this is not the sole pathway of DNA synthesis,
the inhibitory effect of these calcium antagonists is very
much smaller when assessed by cell counting [14,23].
Thus, the inhibition of growth factor activity to induce
thymidine kinase activity is a superior measure of growth
factor activity producing results which reflect the cell
number response.
The cardiovascular effects and potential negative out-
comes associated with rosiglitazone therapy have been the
subject of recent controversy [18]. A meta analysis showed
that rosiglitazone therapy was associated with statistically
significantly higher rates of myocardial infarction and car-
diovascular death [18]. Notably a similar analysis showed
that this apparently higher risk of cardiovascular misad-
venture did not apply to the other clinical TZD, pioglita-
zone, for which a lower risk of cardiovascular events was
calculated [24]. However, an alternative analysis of the
rosiglitazone data, an analysis considering for example
the role of omitting studies in which there were zero car-
diovascular events has shown that the odds ratio for
excess cardiovascular events associated with rosiglitazone
therapy is much lower and not statistically significant [19]
The blood glucose lowering action of TZDs are beneficial
in terms of reductions in microvascular complications
which are very closely linked to long term estimates of gly-
caemia [25-27]. However, more than glucose lowering
actions are required to manifest beneficial outcomes on
cardiovascular disease such as strokes and heart attacks
[28]. The lack of human efficacy of TZDs towards cardio-
vascular disease in initial trials [29] is surprising in view of
the overwhelmingly positive occurrence of beneficial
actions in cell and animal models for these compounds
[30-33]. Nevertheless, human therapeutic experience isCardiovascular Diabetology 2007, 6:33 http://www.cardiab.com/content/6/1/33
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the definitive factor and further results from clinical trials
will provide information and guidance to the ultimate
usefulness of this class of compound [34]. In terms of
macrovascular disease the major contributing factors are
inflammation, oxidation and the retention of atherogenic
lipoproteins by extracellular matrix molecules particularly
the proteoglycan, biglycan [35,36]. The role of proteogly-
cans was demonstrated recently in a human pathology
study in coronary arteries in which it was shown that
atherosclerosis commences with the deposition lipopro-
teins associated with the expression of biglycan in the
outer layer of the diffuse intimal thickenings [7]. We
recently reported on the action of oral anti-hyperglycae-
mic agents to modify the synthesis and structure of prote-
oglycans and in accord with the present study it was
shown that TZDs are the only group with direct vascular
actions [37]. In the present study we observed that the
biguanide phenformin inhibited vSMC proliferation and
that finding is in accord with our earlier observation that
it inhibits protein synthesis in these cells [37]. Metformin
appears to be the only non-TZD that shows favourable
outcomes on macrovascular disease UKPDS [38] and
which may be associated with the important role of insu-
lin resistance in macrovascular disease [39].
Conclusion
This data supports numerous studies in which TZDs have
appreciable direct actions on vSMCs that if expressed in
vivo would be beneficial in reducing cardiovascular dis-
ease. Our finding that the action of TZDs is enhanced
under high glucose conditions is also positive for the use
of these compounds in the setting of diabetes. Further
understanding is required to match the clinical utility of
these agents with the multitude of in vitro and in vivo data
which supports a role in the prevention of cardiovascular
disease associated with diabetes.
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